For instance, immunomodulatory interventions such as tocilizumab (a blocker of IL-6 receptor), adalimumab (anti-TNF antibody), and eculizumab (anti-C5 antibody) can effectively mitigate the CRS, which are nevertheless incapable of reducing mortality in COVID-19 patients (Bian et al. 2020; Mehta...
Plasma- pheresis is initiated in most of patients, and eculizumab has been tried in a small number of patients. The role of these two therapies in malignancy-associated TMA is controversial and should be discussed on a case-by-case basis [51, 102, 121, 140]. Conclusion The novel drug ...
There were no deaths in the eculizumab trials during the initial 26-week evaluation period. However, deaths unrelated to the study drug in this very severe disease have been reported during follow-up evaluation, mainly attributed to concomitant disease or conditions, such as those observed in this...